Gene · 6892
Papers1,693
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 1,693
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Incorporating the Molecular Mimicry of Environmental Antigens into the Causality of Autoimmune Hepatitis. | Dig Dis Sci | 2023 | 37160542 | PubTator, text mining | PubMed |
| Cancer Resistance to Immunotherapy: Comprehensive Insights with Future Perspectives. | Pharmaceutics | 2023 | 37111629 | PubTator, text mining | PubMed |
| Anti-PD-1 therapy achieves favorable outcomes in HBV-positive non-liver cancer. | Oncogenesis | 2023 | 37080999 | PubTator, text mining | PubMed |
| Uncovering a novel role of focal adhesion and interferon-gamma in cellular rejection of kidney allografts at single cell resolution. | Front Immunol | 2023 | 37063857 | PubTator, text mining | PubMed |
| Omics are Getting Us Closer to Understanding IgA Nephropathy. | Arch Immunol Ther Exp (Warsz) | 2023 | 37060455 | PubTator, text mining | PubMed |
| Regional Variation in the Tumor Microenvironment, Immune Escape and Prognostic Factors in Breast Cancer in Sub-Saharan Africa. | Cancer Immunol Res | 2023 | 37058582 | PubTator, text mining | PubMed |
| Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors. | Clin Cancer Res | 2023 | 37053197 | PubTator, text mining | PubMed |
| Assessment of Impact of Human Leukocyte Antigen-Type and Cytokine-Type Responses on Outcomes after Targeted Therapy Currently Used to Treat Chronic Lymphocytic Leukemia. | J Clin Med | 2023 | 37048814 | PubTator, text mining | PubMed |
| Interferons and Resistance Mechanisms in Tumors and Pathogen-Driven Diseases-Focus on the Major Histocompatibility Complex (MHC) Antigen Processing Pathway. | Int J Mol Sci | 2023 | 37047709 | PubTator, text mining | PubMed |
| MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer. | Cell Rep Med | 2023 | 37044092 | PubTator, text mining | PubMed |
| Single-cell RNA sequencing highlights intratumor heterogeneity and intercellular network featured in adamantinomatous craniopharyngioma. | Sci Adv | 2023 | 37043580 | PubTator, text mining | PubMed |
| A pan-cancer analysis of DDR1 in prognostic signature and tumor immunity, drug resistance. | Sci Rep | 2023 | 37031216 | PubTator, text mining | PubMed |
| Effects of prenatal pesticide exposure on the fetal brain and placenta transcriptomes in a rodent model. | Toxicology | 2023 | 37019170 | PubTator, text mining | PubMed |
| The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer-Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy. | Cancers (Basel) | 2023 | 36980527 | PubTator, text mining | PubMed |
| FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer. | Gut | 2023 | 36977556 | PubTator, text mining | PubMed |
| Genome-wide identification of RNA modification-related single nucleotide polymorphisms associated with rheumatoid arthritis. | BMC Genomics | 2023 | 36973646 | PubTator, text mining | PubMed |
| Comprehensive analysis of the prognosis, tumor microenvironment, and immunotherapy response of SDHs in colon adenocarcinoma. | Front Immunol | 2023 | 36949947 | PubTator, text mining | PubMed |
| Proteomic and phosphoproteomic characteristics of the cortex, hippocampus, thalamus, lung, and kidney in COVID-19-infected female K18-hACE2 mice. | EBioMedicine | 2023 | 36933413 | PubTator, text mining | PubMed |
| Effects of calreticulin mutations on cell transformation and immunity. | J Cell Mol Med | 2023 | 36916035 | PubTator, text mining | PubMed |
| Secretogranin II influences the assembly and function of MHC class I in melanoma. | Exp Hematol Oncol | 2023 | 36906639 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6892/papers?page=9